HK1163704A1 - 單克隆抗體的拮抗活性的調節方法 - Google Patents

單克隆抗體的拮抗活性的調節方法

Info

Publication number
HK1163704A1
HK1163704A1 HK12104204.0A HK12104204A HK1163704A1 HK 1163704 A1 HK1163704 A1 HK 1163704A1 HK 12104204 A HK12104204 A HK 12104204A HK 1163704 A1 HK1163704 A1 HK 1163704A1
Authority
HK
Hong Kong
Prior art keywords
modulation
monoclonal antibody
antagonistic activity
antagonistic
activity
Prior art date
Application number
HK12104204.0A
Other languages
English (en)
Inventor
．格奇
．沃琴
Original Assignee
皮埃爾法布雷醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2008/055664 external-priority patent/WO2010064090A1/en
Application filed by 皮埃爾法布雷醫藥公司 filed Critical 皮埃爾法布雷醫藥公司
Publication of HK1163704A1 publication Critical patent/HK1163704A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
HK12104204.0A 2008-12-02 2012-04-28 單克隆抗體的拮抗活性的調節方法 HK1163704A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2008/055664 WO2010064090A1 (en) 2008-12-02 2008-12-02 Process for the modulation of the antagonistic activity of a monoclonal antibody
US18440609P 2009-06-05 2009-06-05
PCT/EP2009/066205 WO2010063746A1 (en) 2008-12-02 2009-12-02 Process for the modulation of the antagonistic activity of a monoclonal antibody

Publications (1)

Publication Number Publication Date
HK1163704A1 true HK1163704A1 (zh) 2012-09-14

Family

ID=41668304

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12104204.0A HK1163704A1 (zh) 2008-12-02 2012-04-28 單克隆抗體的拮抗活性的調節方法

Country Status (22)

Country Link
US (3) US9676839B2 (zh)
EP (2) EP2370464B1 (zh)
JP (1) JP5832899B2 (zh)
KR (2) KR20110091519A (zh)
CN (2) CN105820241A (zh)
AR (1) AR074438A1 (zh)
AU (1) AU2009324145B2 (zh)
BR (1) BRPI0923228B1 (zh)
CA (1) CA2744065C (zh)
DK (1) DK2370464T3 (zh)
ES (1) ES2600254T3 (zh)
GE (1) GEP20135931B (zh)
HK (1) HK1163704A1 (zh)
IL (1) IL213272A (zh)
MA (1) MA32838B1 (zh)
MX (1) MX2011005569A (zh)
NZ (1) NZ592830A (zh)
SA (1) SA109300723B1 (zh)
TN (1) TN2011000253A1 (zh)
TW (1) TWI631341B (zh)
WO (1) WO2010063746A1 (zh)
ZA (1) ZA201103831B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
AU2011226103C1 (en) 2010-03-10 2016-04-28 Genmab A/S Monoclonal antibodies against c-Met
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN107172880B (zh) * 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
EP3699198A1 (en) 2014-11-17 2020-08-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
JP6773679B2 (ja) 2015-03-30 2020-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
WO2018081448A1 (en) * 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
JP2021535142A (ja) 2018-08-31 2021-12-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004309275B2 (en) 2003-12-25 2010-12-23 Kyowa Kirin Co., Ltd. Mutants of anti-CD40 antibody
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
JP5142998B2 (ja) * 2005-07-18 2013-02-13 アムジエン・インコーポレーテツド ヒト抗ｂ７ｒｐ１中和抗体
US8652469B2 (en) * 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
KR20090013763A (ko) * 2006-03-23 2009-02-05 기린 파마 가부시끼가이샤 인간 트롬보포이에틴 수용체에 대한 아고니스트 항체
EP2004693B1 (en) * 2006-03-30 2012-06-06 Novartis AG Compositions and methods of use for antibodies of c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
US20150239958A1 (en) 2015-08-27
ZA201103831B (en) 2012-01-25
AU2009324145A1 (en) 2010-06-10
BRPI0923228A2 (pt) 2021-02-09
EP3048113A1 (en) 2016-07-27
DK2370464T3 (en) 2016-11-21
AR074438A1 (es) 2011-01-19
US20130109839A1 (en) 2013-05-02
AU2009324145B2 (en) 2015-01-22
US20110263830A1 (en) 2011-10-27
CN102232086B (zh) 2016-03-16
EP2370464B1 (en) 2016-07-27
IL213272A0 (en) 2011-07-31
ES2600254T3 (es) 2017-02-08
IL213272A (en) 2017-08-31
BRPI0923228B1 (pt) 2022-03-03
MA32838B1 (fr) 2011-11-01
KR20110091519A (ko) 2011-08-11
TW201024734A (en) 2010-07-01
CN105820241A (zh) 2016-08-03
CN102232086A (zh) 2011-11-02
TN2011000253A1 (en) 2012-12-17
KR20170021378A (ko) 2017-02-27
WO2010063746A1 (en) 2010-06-10
GEP20135931B (en) 2013-10-10
SA109300723B1 (ar) 2014-10-27
CA2744065A1 (en) 2010-06-10
US9676839B2 (en) 2017-06-13
TWI631341B (zh) 2018-08-01
NZ592830A (en) 2013-03-28
CA2744065C (en) 2017-09-12
JP2012510281A (ja) 2012-05-10
RU2011124749A (ru) 2013-01-10
JP5832899B2 (ja) 2015-12-16
KR101971806B1 (ko) 2019-08-27
EP2370464A1 (en) 2011-10-05
MX2011005569A (es) 2011-06-16

Similar Documents

Publication Publication Date Title
HK1163704A1 (zh) 單克隆抗體的拮抗活性的調節方法
HRP20181360T1 (hr) Anti-cd28 humanizirana protutijela
EP2331579A4 (en) MONOCLONAL ANTIBODIES
ZA201005348B (en) Humanized anti-c5ar antibodies
SG10201601279SA (en) Monoclonal Antibody STRO-4
ZA200809065B (en) Humanized c-Kit antibody
ZA201104110B (en) Antibodies that specifically block the biological activity of a tumor antigen
IL204835A0 (en) Humanized antibody
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
HK1168871A1 (zh) 單克隆抗體
IL217919A0 (en) Humanized anti-cdcp1 antibodies
EP2217626A4 (en) EPITOP FOR NEUTRALIZING ANTIBODIES
IL214959A0 (en) Humanized pcrv antibody having anti-pseudomonal activity
EP2239323A4 (en) HUMANIZED ANTI-INEGRINE 9 HUMAN ANTIBODY
GB0804686D0 (en) Humanized antibody
GB0804687D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody
TWI348915B (en) Anti-vegf monoclonal antibody
AU2008903401A0 (en) Anti-C5L2 monoclonal antibodies
GB0706965D0 (en) Humanized antibody
GB0706964D0 (en) Humanized antibody
GB0706963D0 (en) Humanized antibody